Early Access — free while we kick the tires
EdgarHawk

Lee Jennifer Kayden

EVP, Head of North America

Officer
1 filing analyzed · 1 company · Latest 2024-11-13

Companies

Company Buys Sells Direction
RHYTHM PHARMACEUTICALS, INC. RYTM 0 7 Net selling

Activity

November 2024
high
Sell
66,861 shares
$4,434,882
Significance 7/10

EVP Lee Jennifer Kayden sold 66.9K shares (98.6% of holdings) for $4.4M at avg $66.33 on 2024-11-11 at RYTM

Lee Jennifer Kayden, EVP and Head of North America at Rhythm Pharmaceuticals, executed 4 separate sales totaling 66,861 shares for $4,434,882.43, reducing her holdings by 98.6% from 67,833 to 972 shares. The sales occurred at prices ranging from $65.68 to $68.43, with a blended average of $66.33, at a time when the stock trades at $60.07 (currently -10.8% from its 52-week high of $67.33). While the company demonstrates strong revenue growth of +227.6% year-over-year, it remains unprofitable with a net loss of $-43,641,000.00 in its most recent full fiscal year and a quarterly revenue of $33,251,000.00. The near-complete liquidation of a senior executive's position warrants examination of any internal context, though the absence of a 10b5-1 trading plan designation suggests this was discretionary activity.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access